Results 171 to 180 of about 5,464,336 (251)

Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events. [PDF]

J Clin Exp Hematop, 2022
Ishitsuka K, Yokoyama Y, Baba N, Matsuoka R, Sakamoto N, Sakamoto T, Kusakabe M, Kato T, Kurita N, Nishikii H, Sakata-Yanagimoto M, Obara N, Hasegawa Y, Chiba S.   +13 more
europepmc   +1 more source

Incidence, Risk Factors and Management of Adverse Events in Contemporary Real‐World Care of Children with Juvenile Idiopathic Arthritis

Arthritis Care &Research, Accepted Article.
Objective We describe the frequency, risk factors, severity, and management of actionable and serious adverse events (AAE and SAE) in children with newly diagnosed Juvenile Idiopathic Arthritis (JIA) in Canada. Methods We enrolled patients within 3 months of JIA diagnosis in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry,
Bashayer Alnuaimi, Roberta A. Berard, Jean‐Philippe Proulx‐Gauthier, Heinrike Schmeling, Michelle Batthish, Gilles Boire, Adam M. Huber, Dax G. Rumsey, Jaime Guzman, Gaëlle Chédeville, The CAPRI registry Investigators   +10 more
wiley   +1 more source

Factors associated with immune‑related severe adverse events (Review). [PDF]

Mol Clin Oncol
Su Z, Guan M, Zhang L, Lian X.
europepmc   +1 more source

Prevalence of Dietary Supplement Use and Potential Medication Interactions Among Adults With Systemic Lupus Erythematosus

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to characterize the prevalence and correlates of dietary supplement use, identify commonly used supplements, and evaluate potential supplement–medication interactions among adults with systemic lupus erythematosus (SLE).
Sarah L. Patterson, Russell Ellyson, Jessica Fitzpatrick, Ghizlane Yaakoubi, Bradley Pearce, S. Sam Lim, Jinoos Yazdany, Laura C. Plantinga   +7 more
wiley   +1 more source

Association of First-Trimester Maternal Biomarkers with Preeclampsia and Related Maternal and Fetal Severe Adverse Events. [PDF]

Int J Mol Sci
Camacho-Carrasco A, Montenegro-Martínez J, Miranda-Guisado ML, Muñoz-Hernández R, Salsoso R, Fatela-Cantillo D, García-Díaz L, Stiefel García-Junco P, Mate A, Vázquez CM, Alfaro-Lara V, Vallejo-Vaz AJ, Beltrán-Romero LM.   +12 more
europepmc   +1 more source

Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021. [PDF]

Arch Public Health, 2021
Konu YR, Gbeasor-Komlanvi FA, Yerima M, Sadio AJ, Tchankoni MK, Zida-Compaore WIC, Nayo-Apetsianyi J, Afanvi KA, Agoro S, Salou M, Landoh DE, Nyansa AB, Boko E, Mijiyawa M, Ekouevi DK.   +14 more
europepmc   +1 more source

A Scoping Review and Meta‐Analysis of Proportions of Central Nervous System Manifestations Reported in Patients with Sjögren's Disease

Arthritis Care &Research, EarlyView.
Objective The objective of this scoping review was to synthesize evidence on the proportion of individuals living with Sjögren's disease who experience central nervous system (CNS) manifestations. Methods We searched MEDLINE (via PubMed) and Embase from 1980 through January 29, 2026, and the ECRI Guidelines Trust from 2020 through January 29, 2026 ...
Arun Varadhachary, Ghaith Noaiseh, Julie Frantsve‐Hawley, Frederick B. Vivino, Jennifer A. McCombe, Shamik Bhattacharyya, E. Sherwood Brown, Andrew R. Carey, Robert Fox, Thomas Grader‐Beck, Janet E. Lewis, Stephen Maitz, Steven Mandel, Astrid Rasmussen, George Sarka, R. Hal Scofield, Daniel J. Wallace, Rochelle Zak, Kristie Cox, Katherine M. Hammitt, Steven Carsons, Nancy Carteron   +21 more
wiley   +1 more source

Reporting Matters: Severe Adverse Events in Soft Tissue Sarcoma Therapy-A 30-Year Systematic Review of Placebo- and Non-Systemic-Controlled Randomized Trials. [PDF]

Cancers (Basel)
Aeschbacher R, Fuchs B, Studer G, Heesen P.   +3 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Secukinumab in Giant Cell Arteritis: An Italian Multicenter Cohort Study

Arthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate the real‐world effectiveness and safety of secukinumab in patients with giant cell arteritis (GCA). Methods This multicenter retrospective study included patients with GCA who received secukinumab at 14 Italian centers with at least six months of follow‐up.
Luca Iorio, Federica Davanzo, Caterina Ricordi, Milena Bond, Ruggiero Mascolo, Jacopo Mora, Alessandro Tomelleri, Angelo Fassio, Francesca Cuzzocrea, Sara Monti, Edoardo Conticini, Fabiola Atzeni, Paolo Delvino, Carlotta Nannini, Augusta Ortolan, Francesco Pollastri, Ester Vivaldelli, Chiara Marvisi, Paola Toniati, Antonio Brucato, Alessandra Milanesi, Francesca Regola, Enrico Tombetti, Lorenzo Dagna, Roberta Ramonda, Christian Dejaco, Luca Quartuccio, Carlo Salvarani, Roberto Padoan   +28 more
wiley   +1 more source

Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature. [PDF]

Ann Transl Med, 2021
Bao Z, Sun X, Chen W, Tang W, Gao B, Xiang Y.   +5 more
europepmc   +1 more source